EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Surrogate Endpoints in Regulatory Decision‐Making

Linda J B Jeng iD, Jeffrey Siegel iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Linda J B Jeng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Informatics, Research, and Biomarker Development, Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Eva…. Hauptthemen laut MEDLINE: Biomarkers, Drug Approval, Endpoint Determination, Decision Making. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To support approval, FDA requires substantial evidence of effectiveness that demonstrates a drug improves meaningful clinical outcomes as measured by how a patient feels, functions, or survives. Effectiveness is measured directly (e.g., by patient‐reported outcome or other clinical outcome assessment) or indirectly (i.e., by use of a surrogate endpoint (SE) that predicts how a patient will feel, function, or survive). Use of biomarkers as SEs can hasten drug development for patients with unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersDrug ApprovalEndpoint DeterminationDecision MakingHumansUnited States Food and Drug AdministrationUnited StatesPatient Reported Outcome MeasuresClinical Trials as TopicDrug Development

Stichwörter der Autor:innen

biomarkersdrug developmentsurrogate endpoints

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Division of Biomedical Informatics, Research, and Biomarker Development, Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
  • Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.

ORCID-Profile: Linda J B Jeng, Jeffrey Siegel

Zitieren

APA

Jeng, L. J. B., & Siegel, J. (2025). Surrogate Endpoints in Regulatory Decision‐Making. Clinical and Translational Science. https://doi.org/10.1111/cts.70445

Vancouver

Jeng LJB, Siegel J. Surrogate Endpoints in Regulatory Decision‐Making. Clinical and Translational Science. 2025. doi:10.1111/cts.70445

BibTeX
@article{Jeng2025,
  author = {Jeng, Linda J B and Siegel, Jeffrey},
  title = {Surrogate Endpoints in Regulatory Decision‐Making},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70445}
}
Kostenlos starten →